£6M initial fundraising
Successful phase II results in cat allergy
3rd funding round (£15M)
Positive phase II results in house dust mite & ragweed allergies
£60M investment round
Start of phase III in cat allergy
Results from phase II cat allergy study show four-dose treatment maintains improvement 2 years later
18 March: Circassia raises £200M in successful IPO on the London Stock Exchange
Circassia (CIR:LSE) is a speciality biopharmaceutical company focused on the development of novel immunotherapies. These are designed to treat a range of common allergies and autoimmune conditions by controlling patients’ inappropriate immune responses. Our most advanced product, Cat-SPIRE, has achieved highly impressive results in clinical studies, and is currently in the final phase of testing for cat allergy.
Circassia discovered and developed ToleroMune® technology and, supported by lead shareholders Invesco Perpetual, Imperial Innovations and Lansdowne, made strong progress as a private company. We expanded our portfolio of treatments, raised significant investment and successfully completed numerous clinical studies, all of which culminated in a successful initial public offering on the London Stock Exchange on 18 March 2014. To date, the Company has raised over £300 million in investment. Circassia also maintains strong links with allergy experts, and our joint venture with McMaster University (Hamilton, Canada), Adiga Life Sciences Inc, is pursuing promising new science in the field.
Circassia’s ultimate ambition is to build a successful immunotherapy company, improving patients’ lives around the world. In the short term, we plan to complete the development and launch of our first allergy treatment, Cat-SPIRE. To achieve this, we are building our commercial capabilities and advancing our phase III programme. With the support of our investors, Circassia is making good progress towards meeting its long-term goal.